GSK wins US approval for Nelkarmi in previously treated ALK-positive lung cancer
- Approval is based on phase I/II ALKOVE-1, which included 222 patients with previously treated ALK-positive NSCLC.
- Confirmed response rates were 49% after alectinib alone and 32% after at least two ALK inhibitors plus chemotherapy.
- Intracranial response rates were 55% and 26%, respectively, among patients with measurable CNS metastases.
- Common adverse reactions included hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue.
FDA approval
The FDA granted accelerated approval to GSK’s Nelkarmi (neladalkib) for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) previously treated in the unresectable or metastatic setting. Eligible patients must have received either alectinib as their only prior ALK inhibitor, or at least two ALK inhibitors and platinum-based chemotherapy.
Clinical results
Approval was based on the phase I/II ALKOVE-1 trial. Among patients previously treated with alectinib alone, the confirmed overall response rate was 49% (33/67); among those treated with at least two ALK inhibitors and chemotherapy, it was 32% (50/155). Responses lasted at least 12 months in 52% and 51% of responders, respectively.
For patients with measurable central nervous system metastases, intracranial response rates were 55% after alectinib alone and 26% after at least two ALK inhibitors and chemotherapy.
Safety and further evaluation
The most common adverse reactions, occurring in at least 20% of patients, were hepatotoxicity, musculoskeletal pain, constipation, dysgeusia, peripheral neuropathy, edema and fatigue. Adverse reactions led to permanent discontinuation in 5% of patients, most often because of hepatotoxicity.
Nelkarmi is also being evaluated in the ongoing phase III ALKAZAR trial in patients who have not received an ALK inhibitor, and in other solid tumours.
Source: GSK